The purpose of this study is to see:
1. If using these two drugs (carfilzomib and belatacept) together is safe
2. If the use of these two study drugs in addition to the usual immunosuppression for kidney transplant patients can improve your transplanted kidney function by lowering the antibodies you have against your transplanted kidney
3. If the study drugs effect the immune cells that were responding to your donor kidney. And, whether blood or urine tests can measure signs of inflammation and kidney cell injury
4. If using new computer techniques can help describe important changes seen on biopsy in your donated kidneys
The primary objective is to assess the efficacy of carfilzomib and belatacept therapy when added to current treatment with steroids and maintenance immunosuppression, compared to conventional treatment alone, to improve the clinical outcome of renal transplant patients with active and chronic - active ABMR occurring more than 6 months after renal transplantation or less than 6 months post-transplant with persistent refractory Antibody-Mediated Rejection (ABMR)

开始日期2025-06-30

申办/合作机构

National Institute of Allergy & Infectious Diseases

NCT06892522

/ Not yet recruiting临床1期

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of Etentamig Monotherapy or Etentamig Combinations in Subjects With Multiple Myeloma

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine the safety, efficacy, and pharmacokinetics of Etentamig in adult participants with MM.
Etentamig is an investigational drug being developed for the treatment of MM. This study is broken into 4 substudies and each substudy consists of a dose escalation phase and dose expansion phase. Participants will receive escalating doses of etentamig alone or in combination with daratumumab and lenalidomide (DR), carfilzomib and dexamethasone (Kd) or lenalidomide (R). This will be followed by etentamig at the dose levels established during the escalation phases alone or in combination with DR, Kd, R. The participants can also receive daratumumab, lenalidomide and dexamethasone (DRd), R, or daratumumab, carfilzomib, and dexamethasone (DKd) as a comparator in the dose expansion phases. Around 440 adult participants with MM will be enrolled at approximately 50 sites worldwide
In all substudies, participants will receive escalating doses of etentamig as Intravenous (IV) infusions, alone or in combination with DR, R or Kd, followed by IV infusions of etentamig at the dose levels established during the escalation phases alone or in combination with IV and oral DRd, DKd, or R. The study duration is approximately 130 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.

开始日期2025-06-02

申办/合作机构

AbbVie, Inc.

NCT06627751

/ Recruiting临床2期IIT

Phase II Clinical Trial of Mezigdomide/Carfilzomib/Dexamethasone (MeziKD) in Patients With Relapsed or Refractory Multiple Myeloma (MM) With Extramedullary Disease (EMD)

This phase II trial studies how well mezigdomide/carfilzomib/dexamethasone (MeziKD) works in treating patients with multiple myeloma (MM) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory) and have tumors from myeloma cells outside the bone marrow in the soft tissues or organs of the body (extramedullary disease [EMD]). Mezigdomide blocks important processes in myeloma cells and may lead to modulation of the immune system, including activation of T-lymphocytes, and downregulation of the activity of other proteins, some of which play key roles in the proliferation of certain cancer cell types. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Dexamethasone is a type of corticosteroid and is used to kill myeloma cells. It is used with other drugs to treat multiple myeloma. Giving MeziKD may kill more cancer cells in patients with relapsed/refractory multiple myeloma (RRMM) with EMD.

开始日期2025-05-01

申办/合作机构

Roswell Park Comprehensive Cancer Center

100 项与卡非佐米相关的临床结果

登录后查看更多信息

100 项与卡非佐米相关的转化医学

登录后查看更多信息

100 项与卡非佐米相关的专利（医药）

登录后查看更多信息

2,552

项与卡非佐米相关的文献（医药）

2025-07-01·BIOMEDICINE & PHARMACOTHERAPY

Population pharmacokinetics of cefazolin in neurosurgical antibiotic prophylaxis

Article

作者: Legros, Vincent ; Duflot, Thomas ; Marlier, Benoit ; Malinovsky, Jean-Marc ; Feliu, Catherine ; Riffault, Maxime ; Scala-Bertola, Julien ; Djerada, Zoubir ; Kleiber, Jean-Charles ; Rouget, David ; Konecki, Céline

In neurosurgery, cefazolin (CFZ) is typically recommended at a dose of 2-gram within 60 minutes prior to surgical incision. However, due to the reported poor cerebrospinal fluid (CSF) penetration of CFZ, we conducted a population pharmacokinetic study to assess the adequacy of a 2-gram CFZ dosing regimen against the most common pathogens found in neurosurgical patients. If necessary, alternative CFZ dosing strategies were identified to achieve effective CSF concentrations. Adult patients undergoing neurosurgery were considered for inclusion in a prospective, observational, single-center study. After intravenous administration of CFZ 2-gram, blood and CSF samples were collected to determine CFZ concentrations. Population pharmacokinetic modeling of CFZ was performed using a non-linear mixed-effects approach and different dosing regimens were evaluated pharmacodynamically via Monte Carlo simulations. A total of 147 plasma and 42 CSF samples from 23 patients were analyzed. The median CFZ concentrations in plasma and CSF were 140.5 and 7.8 mg/L, respectively. The final model selected was a two-compartment model with an additional CSF compartment without covariates. The standard 2 g CFZ dose was inadequate in most cases. In contrast, intermittent administration of 1 g every hour following an initial bolus of 4-5 g, or continuous infusion at a rate of 1.625 g/h after a 6 g bolus provided better target attainment. The standard 2 g CFZ dose for neurosurgical antibiotic prophylaxis should be reassessed. The alternative dosing regimens proposed in this study warrant evaluation in future clinical trials.

2025-07-01·Translational Oncology

Carfilzomib promotes Iodine-125 seed radiation-induced apoptosis, paraptosis, and ferroptosis in esophageal squamous cell carcinoma by aggravating endoplasmic reticulum stress

Article

作者: Wang, Hao ; Sun, Bai ; Hu, Wen-Wei ; Qiang, Wei-Guang ; Wang, Chao ; Yuan, Ye ; Shi, Hong-Bing ; Zha, Yin-Lin

Iodine-125 (¹²⁵I) seed brachytherapy has been applied to treat various malignant tumors such as esophageal cancer, however, radioresistance can reduce its efficacy. Endoplasmic reticulum stress (ERS) and subsequent unfolded protein response (UPR) is one of the core mechanisms of ¹²⁵I seed radiation-induced cell death, thus aggravating ERS has been considered a promising sensitization strategy. Herein, we show that combination therapy of an irreversible proteasome inhibitor carfilzomib (CFZ) and ¹²⁵I seed radiation displayed strong anti-tumor effect on esophageal squamous cell carcinoma (ESCC). Mechanistically, ERS and UPR regulated multiple cell death modalities induced by the combination therapy, including apoptosis, paraptosis, and ferroptosis. ¹²⁵I seed radiation induced reactive oxygen species (ROS) production, DNA damage, p53 activation, and apoptosis. CFZ promoted ROS production, and augmented ¹²⁵I seed radiation-induced apoptosis via the mitochondrial pathway, which was mediated by the UPR-C/EBP homologous protein (CHOP) pathway and was independent of the p53 pathway. CFZ enhanced ¹²⁵I seed radiation-induced intracellular Ca²⁺ overload, protein ubiquitination, ERS, and UPR, consequently promoting paraptosis. ¹²⁵I seed radiation induced accumulation of intracellular Fe²⁺ and lipid peroxides but upregulated the expression of ferroptosis inhibitors, SLC7A11 and glutathione peroxidase 4 (GPX4). The combination therapy promoted ferroptosis by enhancing the accumulation of intracellular Fe²⁺ and downregulating GPX4 expression. The mouse experiment demonstrated that CFZ can promote the efficacy of ¹²⁵I seed radiation with good tolerance. Our findings suggest that combination therapy of ¹²⁵I seed radiation and CFZ is associated with multiple cell death modalities and may serve as a promising therapeutic strategy for ESCC.

2025-06-01·Materials Today Bio

Enhanced anticancer effect of carfilzomib by codelivery of calcium peroxide nanoparticles targeting endoplasmic reticulum stress

Article

作者: Wu, Xuan ; Wang, Jianfang ; Chen, Xiuping ; Chen, Jian-Li ; Xia, Xinyue ; Zhu, Xiao-Ming ; Chen, Xu ; Yin, Dan

Encouraged by the clinical success of proteasome inhibitors treating hematological malignancy, continuous efforts are being made to improve their efficacy and expand their applications to solid tumor therapy. In this study, liposomes were used to encapsulate the proteasome inhibitor carfilzomib (CFZ) and calcium peroxide (CaO₂) nanoparticles for effective combination therapy targeting the interplay between calcium overload and oxidative stress. Low-dose CaO₂ synergistically enhances the anticancer effect of CFZ in the human glioblastoma U-87 MG cells. The reactive oxygen species (ROS) generation and glutathione depletion by low-dose CaO₂ complement CFZ-induced ubiquitinated protein accumulation further triggering endoplasmic reticulum (ER) stress leading to calcium overload and mitochondrial dysfunction. The liposome-based codelivery system is capable of transporting CFZ and CaO₂ simultaneously to the tumor, and results in a superior antitumor effect in U-87 MG tumor-bearing mice compared with monotherapy. Taken together, CaO₂ holds great potential to sensitize proteasome inhibitors in the treatment of solid tumors, and this work also presents a new combination therapy strategy targeting the crosstalk between proteasome inhibitors and oxidative stress for future cancer therapy.

411

项与卡非佐米相关的新闻（医药）

2025-05-31

·小药说药

Nature Reviews Cancer (IF 72.5) | 癌症治疗中的靶向蛋白质降解技术！

靶向蛋白质降解（TPD）旨在重新编程泛素-蛋白酶体系统的目标特异性，以诱导治疗性蛋白的选择性泛素化和降解。自20多年前提出以来，TPD主要由于双功能蛋白降解嵌合体（PROTACs）的设计改进和对分子胶降解剂潜在机制的理解而受到广泛关注。如今，PROTACs正处于首次临床批准的边缘，而对结构和机制的理解再结合新的技术，有望解锁蛋白质降解剂的设计。与此同时，随着新降解模式的发现，TPD领域正以创纪录的速度扩张，超越了分子胶降解剂和PROTACs。近期，Nature Reviews Cancer期刊上公布了一篇名为“Targeted protein degradation for cancer therapy”的综述性文章，在文章里，作者总结了该领域的最新进展，重点关注了新发现的降解模式、癌症治疗中临床降解候选药物的现状以及即将到来的设计方法。文章标题内容要点泛素-蛋白酶体系统介导的蛋白质降解通过细胞内机制和外部刺激在多个层面受到高度调控。药物干预通过重新编程E3泛素连接酶和蛋白酶体来增强、减少或改变选定蛋白的降解，从而利用并模仿这些机制。PROTACs使用专门的配体分别结合目标蛋白和E3连接酶，以诱导它们的接近、泛素转移和有效的蛋白降解。分子胶降解剂增强E3连接酶和目标蛋白之间预先存在的表面互补性，以诱导稳定的三元复合物的形成、泛素化和降解。新的降解策略，如分子内双价胶或模板辅助的共价降解尾，扩展了靶向蛋白降解的应用范围，并模糊了既定模式之间的界限。靶向蛋白降解的成功为其他基于接近诱导的模式铺平了道路，例如蛋白重定位或转录和表观遗传重编程。UPS系统UPS系统机制示意图泛素-蛋白酶体系统（Ubiquitin-Proteasome System,UPS）：是细胞内主要的蛋白质降解途径，负责细胞内80-90%的蛋白质降解。它不仅参与旧的、受损的或错误折叠的蛋白质的清除，还在细胞周期调控、信号转导、基因表达、应激响应等多种细胞过程中发挥关键作用。核心组成：UPS系统的核心组成部分包括泛素（Ubiquitin）、E1泛素激活酶、E2泛素结合酶和E3泛素连接酶，以及蛋白酶体（Proteasome）。泛素化过程：泛素化是一个三步级联反应，涉及（1）激活：泛素被E1泛素激活酶激活。（2）结合：激活后的泛素转移到E2泛素结合酶。（3）连接：E2酶将泛素共价连接到目标蛋白上，这一过程由E3泛素连接酶催化。蛋白质降解：被泛素化的蛋白质被蛋白酶体识别并降解。蛋白酶体由多个亚基组成，形成一个封闭的桶形结构，内部是蛋白水解室。只有被泛素标记的蛋白质才能进入蛋白酶体的水解室进行降解。降解后的短肽被释放到细胞质中，进一步被细胞内的其他酶分解为氨基酸，用于蛋白质的合成。调控机制：UPS系统具有高度的选择性和调控性。E3泛素连接酶的特异性决定了目标蛋白的选择。细胞内有超过600种不同的E3连接酶，每种都能识别特定的目标蛋白。此外，UPS系统还通过多种翻译后修饰（PTMs）和调节蛋白进行调控，确保蛋白质降解的精确性和高效性。生理和病理意义：UPS系统在维持细胞稳态、调控细胞周期、应激响应等方面发挥重要作用。例如，缺氧诱导因子-1α（HIF-1α）在有氧条件下被E3连接酶VHL泛素化并降解，而在缺氧条件下，HIF-1α积累并启动转录反应。在病理状态下，UPS系统的失调与多种疾病相关，如癌症、神经退行性疾病和自身免疫性疾病。因此，UPS系统已成为药物研发的重要靶点，例如蛋白酶体抑制剂硼替佐米和卡非佐米已被用于治疗多发性骨髓瘤。总之，UPS系统是一个复杂而精细的蛋白质降解机制，对细胞的正常功能和疾病的发生发展具有深远影响。PROTAC和分子胶PROTACs和分子胶降解剂实现的靶向蛋白质降解PROTACs和MGDs（分子胶降解剂）是TPD领域的两种主要技术，它们通过诱导目标蛋白的降解来实现治疗效果。PROTACs：是一种异双功能化合物，由两个独立的配体通过化学连接子连接而成。其中一个配体结合目标蛋白，另一个配体结合 E3 泛素连接酶。通过这种设计，PROTACs 能够将目标蛋白和 E3 连接酶拉近，形成一个三元复合体，从而促进目标蛋白的泛素化和随后的蛋白酶体降解。PROTACs 的设计通常遵循“即插即用”策略，利用已有的目标蛋白和 E3 连接酶配体。其目标范围广泛，目前针对多种重要癌蛋白（如雌激素受体、表皮生长因子受体等）的降解剂正在临床开发中。由于某些目标蛋白更容易通过特定的 E3 连接酶降解，因此寻找高亲和力配体以扩展可用的 E3 连接酶种类成为研究重点。MGDs：是一种单价化合物，通过增强目标蛋白和 E3 连接酶之间的相互作用来促进目标蛋白的降解。与 PROTACs 不同，MGDs 通常不直接结合目标蛋白或 E3 连接酶，而是通过结合目标蛋白的相互作用子或改变目标蛋白的构象来增强其与 E3 连接酶的结合亲和力。这种机制类似于“分子胶”，能够增强两个蛋白之间预先存在的表面互补性和内在结合亲和力。MGDs 的作用机制较为复杂，大多数已知的 MGDs 是免疫调节亚胺类药物（IMiDs）的衍生物，如沙利度胺、来那度胺和泊马度胺。这些化合物能够诱导多种目标蛋白的降解，包括 C2H2 锌指蛋白和非锌指蛋白。MGDs 的合理设计较为困难，目前大多数 MGDs 是通过大规模筛选偶然发现的。总之，PROTACs 和 MGDs 都是通过诱导目标蛋白的泛素化和降解来实现治疗效果，但它们的作用机制和设计策略有所不同。PROTACs 通过直接将目标蛋白和 E3 连接酶拉近来促进降解，而 MGDs 则通过增强两个蛋白之间的相互作用来实现降解。这两种技术在癌症治疗中具有巨大的潜力，目前都在积极的临床开发中。新型降解剂新型降解剂模式间接降解剂：通过将目标蛋白的相互作用子与E3连接酶结合，而不是直接将目标蛋白与E3连接酶结合。例如，CR8通过将CDK12招募到Cullin RING E3连接酶适配器DDB1上，使细胞周期蛋白K（Cyclin K）处于适合泛素化的位置，从而促进其降解。这种间接机制为降解那些难以直接靶向的蛋白提供了新的思路。内部分子双价胶（IBGs）：IBGs通过桥接目标蛋白的两个结构域，将它们排列成一种增强与E3连接酶相互作用的构象。例如，IBG1通过结合BRD4的两个溴结构域（BDs），增强了BRD4与DCAF16之间的相互作用，从而促进BRD4的降解。这种设计不仅提高了降解效率，还展示了通过调节蛋白构象来增强降解潜力的新方法。降解尾（Degradation Tails）：通过在非降解配体上添加特定的化学基团，将其转化为高效的降解剂。例如，GNE-0011通过添加一个温和的电philic丙炔胺尾部，能够诱导BRD2和BRD4的降解。这种策略为设计新型降解剂提供了灵活的化学修饰方法，有望应用于多种目标蛋白。核激素受体降解剂（SERDs）：通过置换雌激素受体（ER）的第12螺旋，破坏ER辅激活因子的募集，从而诱导ER的降解。例如，氟维司群（Fulvestrant）通过RNF111触发ER的降解，而其他具有丙烯酸侧链的SERDs则通过UBR5增强ER的内源性周转。这些SERDs为治疗雌激素受体阳性乳腺癌提供了新的选择。SUMO依赖性降解：一些化合物通过诱导目标蛋白的SUMO化，使其被SUMO靶向泛素E3连接酶（STUbLs）识别并降解。例如，WRN抑制剂HRO671通过诱导WRN解旋酶结构域D2相对于D1的180°旋转，将其锁定在一种紧凑的、不活跃的构象中，从而被SUMO E3连接酶PIAS4和STUbL RNF4识别并降解。这种机制为降解那些难以通过传统方法靶向的蛋白提供了新的途径。总之，这些新型降解剂通过创新的机制和设计，扩展了TPD的应用范围。这些降解剂不仅提高了降解效率，还展示了通过调节蛋白构象、化学修饰和SUMO化等方法来增强降解潜力的新思路。TPD的临床优势临床优势靶向蛋白质降解（TPD）是一种新兴的治疗策略，它通过选择性地降解疾病相关蛋白来实现治疗效果。与传统的抑制剂相比，TPD具有多项临床优势：高选择性：TPD通过诱导目标蛋白与E3泛素连接酶的结合，实现对特定蛋白的降解，减少了对非目标蛋白的影响，从而提高了治疗的选择性和特异性。强效力：TPD能够完全降解目标蛋白，彻底消除其功能，比传统抑制剂的部分阻断更为有效，可实现更持久和深入的治疗效果。低剂量：由于TPD的催化作用机制，它们可以在亚化学计量比的剂量下工作，这意味着可以使用较低的剂量来实现治疗效果，从而减少副作用。克服耐药性：TPD可以降解因突变而对抑制剂产生耐药性的蛋白，为治疗耐药性疾病提供了新的策略。宽治疗窗口：TPD的低剂量和高选择性可以扩大治疗窗口，使更多患者受益，同时减少给药频率，提高患者依从性。综上所述，TPD的高选择性、强效力、低剂量和克服耐药性的能力，使其在临床治疗中具有显著的优势，为癌症等疾病的治疗提供了新的希望。公众号内回复“ADC”或扫描下方图片中的二维码免费下载《抗体偶联药物：从基础到临床》的PDF格式电子书！公众号已建立“小药说药专业交流群”微信行业交流群以及读者交流群，扫描下方小编二维码加入，入行业群请主动告知姓名、工作单位和职务。

蛋白降解靶向嵌合体

2025-05-30

·GlobeNewswire-Health Care

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers

30 scientific abstracts will be presented using clonoSEQ for MRD assessment across multiple types of blood cancersSEATTLE, May 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in 30 presentations, including a total of 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 in Chicago and the European Hematology Association (EHA) Congress taking place June 12-15 in Milan. These presentations include notable new data supporting the clinical actionability of clonoSEQ in both multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). "The breadth of new MRD evidence being shared across various blood cancer types at ASCO and EHA this year highlights the transformative impact MRD is having on clinical care and drug development," said Susan Bobulsky, Chief Commercial Officer, MRD, Adaptive Biotechnologies. "These data presentations are a testament to the central role that clonoSEQ MRD testing now plays in clinical management and drug development across lymphoid cancers, particularly when combined with several clonoSEQ data presentations in diffuse large B-cell lymphoma (DLBCL) anticipated at the 18th International Conference on Malignant Lymphoma (iCML) on June 17-21, 2025 in Lugano, Switzerland." Selected presentations include: Data advancing the clinical actionability of clonoSEQ MRD testing Results from MIDAS, a phase 3 randomized study of 718 transplant-eligible, newly diagnosed multiple myeloma (NDMM) patients, demonstrate the use of MRD status to guide therapy post-induction. (ASCO Abstract 7500, June 3, 9:45-9:57 a.m. CDT, S100bc, McCormick Place Convention Center)Interim data from ADVANCE, a phase 2 randomized study of 306 transplant-eligible patients with NDMM shows the impact of MRD-guided assessments post-induction (ASCO Abstract 7503, June 3, 10:21-10:33 a.m. CDT, S100bc, McCormick Place Convention Center)Interim results from VENETOSTOP, a phase 2 study of 66 CLL patients, report the use of MRD status to shorten duration of venetoclax-based therapy. (EHA Abstract PS1568, June 14, 6:30 p.m. CEST, Poster Hall, Milano Convention Centre) Studies utilizing clonoSEQ MRD assessment as a critical indicator of quadruplet regimen efficacy in multiple myeloma Results from the phase 3 IsKia study of 151 transplant-eligible NDMM patients demonstrates increased rates of sustained MRD negativity at 10-6 with isatuximab plus carfilzomib, lenalidomide, and dexamethasone. (ASCO Abstract 7502, June 3, 10:09-10:21 a.m. CDT, S100bc, McCormick Place Convention Center) Follow-up data from PERSEUS, a phase 3 trial of 709 transplant-eligible patients with NDMM reports the impact of sustained MRD negativity status on progression free survival (PFS) with subcutaneous daratumumab plus bortezomib, lenalidomide and dexamethasone (D-VRd) induction and DR maintenance. (ASCO Abstract 7501, June 3, 9:57-10:09 a.m. CDT, S100bc, McCormick Place Convention Center) Results from DREAMM-8, a Phase 3 study in 302 patients with relapsed or refractory multiple myeloma, found superior PFS and higher MRD negativity rates in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) as compared to standard-of-care pomalidomide, bortezomib, and dexamethasone (PVd). (ASCO Abstract 7515, June 2, 9:00-9:06 a.m. CDT E450b, McCormick Place Convention Center) Data to be presented at ASCO: Presentation Type and NumberTitlePresentation TimingB-Cell Acute Lymphoblastic LeukemiaPoster Presentation6540Initial results from a phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) ± rituximab (R) + tafasitamab (tafa) for adults with newly-diagnosed (ND) Philadelphia chromosome negative (Ph-) B lymphoblastic leukemia (B-ALL)Sunday, June 19 a.m.-12 p.m. CDTPoster Presentation6543Brexucabtagene autoleucel (Brexu-cel) as consolidation treatment in adults with B-cell acute lymphoblastic leukemiaSunday, June 19 a.m.-12 p.m. CDTMultiple MyelomaOral Presentation7500*MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trialTuesday, June 39:45-9:57 a.m. CDTOral Presentation7501Subcutaneous daratumumab (Dara) + bortezomib/lenalidomide/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): Analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trialTuesday, June 39:57-10:09 a.m. CDTOral Presentation7502Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial)Tuesday, June 310:09-10:21 a.m. CDTOral Presentation7503*Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trialTuesday, June 310:21-10:33 a.m. CDTOral Presentation7507*Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM)Tuesday, June 311:57 a.m.-12:09 p.m. CDTOral Presentation7515Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd): Analysis from the DREAMM-8 trialMonday, June 29-9:06 a.m. CDTOral Presentation7516Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS studyMonday, June 29:06-9:12 a.m. CDTASCO Oral Presentation7517*Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in newly diagnosed multiple myeloma (NDMM): Outcomes in patients with 1q21+ status in the phase 3 IMROZ studyMonday, June 29:12-9:18 a.m. CDTPoster Presentation7529Daratumumab + bortezomib, lenalidomide, and dexamethasone (DVRd) vs VRd in transplant-ineligible (TIE)/transplant-deferred (TD) newly diagnosed multiple myeloma (NDMM): Phase 3 CEPHEUS trial cytogenetic subgroup analysisSunday, June 19 a.m.-12 p.m. CDTPoster Presentation7535Carfilzomib, lenalidomide, and dexamethasone (KRd) as maintenance therapy after autologous stem-cell transplantation (ASCT) in patients with newly diagnosed multiple myeloma (NDMM)Sunday, June 19 a.m.-12 p.m. CDTASCO Poster Presentation7551*Positron emission tomography with computed tomography (PET/CT) and minimal residual disease (MRD) for efficacy assessment in transplant-ineligible newly diagnosed myeloma (Ti NDMM) patients (pts): IMROZ analysisSunday, June 19 a.m.-12 p.m. CDT Data to be presented at EHA: Presentation Type and NumberTitlePresentation TimingB-Cell Acute Lymphoblastic LeukemiaOral PresentationS112Safety and efficacy of single-agent subcutaneous blinatumomab in adults with relapsed/refractory (R/R) b-cell acute lymphoblastic leukemia (B-ALL): results from a phase 1/2 dose expansion studySunday, June 1511:30-11:45 a.m. CESTOral PresentationS117Safety and efficacy of AZD0486 in adolescent and adult patients with relapsed or refractory b-cell acute lymphoblastic leukemia: early results from the phase 1/2 SYRUS studyFriday, June 135:30-5:45 p.m. CESTPoster PresentationPF372Donor-derived, allogeneic CD19/CD22-CAR T cells with myeloablative graft-engineered Allo-HCT for high-risk B-ALLFriday, June 136:30 p.m. CESTChronic Lymphocytic LeukemiaPoster PresentationPF575Preliminary results of the ongoing multicenter, phase 2 study of retreatment with venetoclax plus obinutuzumab (ReVenG) in patients with recurrent chronic lymphocytic leukemia (CLL)Friday, June 136:30 p.m. CESTPoster PresentationPS1568Using minimal residual disease status to guide venetoclax treatment duration in patients with chronic lymphocytic leukemia: interim results from the phase II VENETOSTOP studySaturday, June 146:30 p.m. CESTFollicular LymphomaPoster PresentationPF881Epcoritamab monotherapy demonstrates deep and durable responses at 3-year follow-up in patients with relapsed/refractory follicular lymphomaFriday, June 136:30 p.m. CESTPoster PresentationPS21504-year update of phase 2 ELARA trial: clinical outcomes of tisagenlecleucel in patients (pts) with high-risk relapsed/refractory follicular lymphoma (R/R FL)Saturday, June 146:30 p.m. CESTMantle Cell Lymphoma Poster PresentationPF882Minimal residual disease with bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: results from the phase 3 ECHO trialFriday, June 136:30 p.m. CESTMultiple MyelomaOral PresentationS201Phase 2 registrational study of anitocabtagene autoleucel for relapsed and/or refractory multiple myeloma (RRMM): updated results from IMMAGINE-1Saturday, June 145:15-5:30 p.m. CESTOral PresentationS205*Minimal residual disease-driven strategy following isatuximab-carfilzomib-lenalidomide-dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma: Primary endpoints of the phase 3 MIDAS trialSunday, June 1511:00-11:15 a.m. CESTOral Presentation S207*A randomized, multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) for the treatment of patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trialSunday, June 1511:30-11:45 a.m. CESTOral PresentationS208*Analysis of sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial)Sunday, June 1511:45 a.m.-12 p.m. CESTPoster PresentationPF727Isa-vrd improves outcomes in high-risk (HR) newly diagnosed transplant-ineligible multiple myeloma (NDMM TI) using the IMS/IMWG consensus HR definition: results from the BENEFIT phase 3 trial (IFM 2020-05)Friday, June 136:30 p.m. CESTPoster Presentation PF729*Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in newly diagnosed multiple myeloma (NDMM): outcomes in patients with 1q21+ status in the phase 3 IMROZ studyFriday, June 136:30 p.m. CESTPoster PresentationPF750Isatuximab, bortezomib, lenalidomide, dexamethasone (Isa-VRd) in patients with transplant-ineligible (TI) newly diagnosed myeloma (NDMM) and plasmacytomas: IMROZ subgroup analysisFriday, June 136:30 p.m. CESTPoster PresentationPF754Interim analysis of MRD-guided maintenance therapy with belantamab mafodotin and lenalidomide after Auto-HCT in newly diagnosed multiple myelomaFriday, June 136:30 p.m. CESTPoster Presentation PS1722*Positron emission tomography with computed tomography and minimal residual disease for efficacy assessment in transplant-ineligible newly diagnosed myeloma patients: IMROZ analysisSaturday, June 146:30 p.m. CEST *Indicates data to be presented at both ASCO and EHA. About clonoSEQ clonoSEQ® is the first and only FDA-cleared in vitro diagnostic (IVD) test for detecting and tracking minimal (or measurable) residual disease (MRD) in patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) using bone marrow, and in patients with chronic lymphocytic leukemia (CLL) using blood or bone marrow. clonoSEQ is also available in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). clonoSEQ is covered by Medicare for MM, CLL, ALL, DLBCL and MCL. clonoSEQ identifies and quantifies DNA sequences in malignant cells—detecting one cancer cell in one million healthy cells—to help clinicians and researchers assess and monitor MRD with precision over time. It delivers standardized, sensitive results that inform treatment decisions, predict outcomes, and detect relapses earlier. clonoSEQ is CE-marked under the EU In Vitro Diagnostic Regulation (IVDR). For intended use details in the EU, see the instructions for use, available on request. To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary. About Adaptive Biotechnologies Adaptive Biotechnologies ("we" or "our") is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. Forward Looking Statements This press release contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections regarding the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. ADAPTIVE INVESTORS Karina Calzadilla, Vice President, Investor Relations and FP&A 201-396-1687 investors@adaptivebiotech.com ADAPTIVE MEDIAErica Jones, Associate Corporate Communications Director206-279-2423media@adaptivebiotech.com

临床2期临床3期临床结果ASCO会议

2025-05-29

·PRNewswire

John Theurer Cancer Center Presents Innovative Cancer Research at Major Annual Cancer Meeting, Offering New Hope for Patients

Presentations and publications address novel therapeutics, molecular biology studies, and global trends for blood cancers and solid tumors HACKENSACK, N.J., May 29, 2025 /PRNewswire/ -- Investigators from Hackensack Meridian John Theurer Cancer Center (JTCC)—part of the National Cancer Institute-designated Lombardi Comprehensive Cancer Center at Georgetown University—and Hackensack University Medical Center are reporting research findings from 32 studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting is the premier event for cancer professionals and takes place in Chicago from May 30 to June 3. "The future of cancer treatment begins with the pioneering exploration being carried out today," notes Andre Goy, MD, chair, vice president, physician-in-chief of oncology, at Hackensack Meridian John Theurer Cancer Center. "We are fortunate to be in a time where many cancers will respond to standard treatments. But for those cancers that don't, it's critical that patients have access to a world-class research program that will yield innovative therapies. At John Theurer Cancer Center, our globally recognized investigators continue to drive the latest oncology advances in cellular therapy, immunotherapy and other areas, enabling improved outcomes for patients across the Hackensack Meridian Health network and beyond." Several studies address novel drug combinations for multiple myeloma, as well as racial disparities in treatment outcomes and the expression of key biomarkers. Investigators are also presenting data on emerging immunotherapies for leukemia and lymphoma, molecular markers predicting disease relapse, and innovative treatment regimens such as all-oral therapies for acute myeloid leukemia. Solid tumor studies focus on disparities in gastric cancer, machine learning applications for breast cancer metastasis, and promising antibody-drug conjugates for lung cancer. Investigations related to melanoma and skin cancer examine circulating tumor DNA as a marker for disease progression, comparative survival analyses based on biomarkers, and the identification of targetable mutations across different skin cancer types. These findings underscore the breadth of ongoing efforts at John Theurer Cancer Center—New Jersey's largest cancer center—to refine therapeutic strategies, enhance precision oncology, and improve patient outcomes. Multiple Myeloma Research Carfilzomib, iberdomide, and dexamethasone in patients with transplant-eligible newly diagnosed multiple myeloma: Updated results from phase 1/2 study Updated results from phase 2b study of selinexor in combination with carfilzomib, daratumumab, or pomalidomide in patients with multiple myeloma relapsing on current therapy Real-world outcomes of patients with multiple myeloma treated with T-cell engagers compared to those treated on clinical trials Impact of racial disparities on efficacy and safety outcomes for patients with relapsing/refractory multiple myeloma receiving T-cell engagers Heterogeneity in the expression of GPRC5D between patients with multiple myeloma Evaluation of immune checkpoint inhibitors and concurrent radiation therapy for the treatment of extramedullary multiple myeloma Global burden of multiple myeloma: Analysis from 1980 to 2021 Efficacy and safety of less frequent dosing with elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3 Leukemia and Lymphoma Peripheral blood cell-free DNA testing as a predictor for relapse post-allogeneic stem cell transplant for acute myeloid leukemia An all-oral regimen of decitabine-cedazuridine plus venetoclax in patients with newly diagnosed acute myeloid leukemia ineligible for intensive induction chemotherapy: Results from a phase 2 cohort of 101 pts Employing novel pan-cancer targets for immunotherapy in leukemias and solid tumors MRD negativity after end of induction in the phase 3 PhALLCON trial: A post hoc analysis Results from the completed dose-finding part of phase 2 study of the innate cell engager acimtamig (AFM13) in combination with AlloNK (AB-101) in relapsed or refractory classical Hodgkin lymphoma (LuminICE-203) Novel analysis of 3-y results from the pivotal EPCORE NHL-1 study: Outcomes in patients with relapsed/refractory large B-cell lymphoma and complete response at 2 years with epcoritamab monotherapy TITANium: An open-label, global multicenter phase 1/2 study of AZD5492, a first-in-class subcutaneous CD8-guided tri-specific T-cell engager, in patients with relapsed or refractory B-cell malignancies Solid Tumor Research Limited changes in the central nervous system immune microenvironment in patients with breast cancer metastasis and capturing these changes using machine learning Relationship between FOLR1 expression and pan-cancer subgroup of tumors with specific transcriptomic profile Disparities and trends in gastric cancer: Incidence, mortality, and stage-specific trends Prevalence of the HPV, EBV, and TTV viral RNA in the plasma of patients with solid and hematologic neoplasms and the detection of a specific immune signature Global trends in soft tissue and extraosseous sarcomas (1980–2021): Regional and economic disparities ZL-1310, a DLL3 antibody-drug conjugate, in patients with extensive stage small cell lung cancer: Phase 1 trial update Ongoing phase 1/2 trial of the hematopoietic progenitor kinase 1 (HPK1) inhibitor NDI-101150 as monotherapy or in combination with pembrolizumab: Clinical safety and efficacy update in clear cell renal cell carcinoma Ipilimumab and nivolumab in patients with metastatic clear cell renal cell carcinoma treated on the phase 3 PDIGREE (Alliance A031704) trial: Results from Step 1 analysis Initial safety and efficacy results from a first-in-human, phase 1/2 study of SAR445877, an anti-PD-1/IL-15 fusion protein, for patients with advanced solid tumors An open-label, phase I trial of the SIRPα monoclonal antibody, BI 770371, alone and in combination with the PD-1 inhibitor ezabenlimab in patients with advanced solid tumors A phase 1 dose escalation and dose expansion study for LNCB74, a B7-H4 targeted antibody drug conjugate, as monotherapy in participants with advanced solid tumors A phase 1, open-label, multi-center study of the safety, tolerability, and efficacy of IPH4502 as a single agent in advanced solid tumors A phase 2 safety and efficacy study of PRT3789 in combination with pembrolizumab in patients with advanced or metastatic solid tumors and a SMARCA4 mutation Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) for newly diagnosed localized prostate cancer Melanoma and Other Skin Cancers Comparison of ctDNA and hematologic ratios as markers of disease progression in early versus late-stage melanoma: A single-center retrospective study Survival analysis based on markers of progression in melanoma: A single-center comparison of survival in patients with high vs low biomarkers Targetable mutations in cutaneous skin cancers: A comparative study across melanoma, squamous cell carcinoma, basal cell carcinoma, and Merkel cell carcinoma SOURCE Hackensack Meridian John Theurer Cancer Center WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ASCO会议临床结果免疫疗法临床1期临床2期

100 项与卡非佐米相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08880	卡非佐米	L01XX45	DB08889

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
多发性骨髓瘤	美国	Onyx Pharmaceuticals, Inc.	2012-07-20

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
难治性多发性骨髓瘤	临床3期	美国	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	日本	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	奥地利	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	保加利亚	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	捷克	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	芬兰	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	法国	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	德国	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	希腊	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	立陶宛	Amgen, Inc.	2019-05-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04268498 (ADVANCE, ASCO2025)	临床2期	多发性骨髓瘤 minimal residual disease (MRD) positive	306	DKRd (Daratumumab, Carfilzomib, Lenalidomide, Dexamethasone)	襯鹹艱獵餘鹽願廠遞築(網網糧艱鬱廠製餘餘夢): adjusted OR = 2.5 (95% CI, 1.5 ~ 4.2) 更多	积极	2025-05-30
				KRd (Carfilzomib, Lenalidomide, Dexamethasone)
NCT01863550 (ENDURANCE, ASCO2025)	临床3期	多发性骨髓瘤 del17p \| t(14;16) \| t(14;20) ... 更多	1,087	VRd (Bortezomib, Lenalidomide, Dexamethasone)	鹹艱齋簾廠憲壓簾繭願(構蓋醖糧襯艱願觸襯簾) = 鑰鑰範糧顧鏇醖鹽壓蓋醖選鹹觸衊齋壓夢糧網 (範鹹積蓋壓夢鏇簾積鬱 )	积极	2025-05-30
				KRd (Carfilzomib, Lenalidomide, Dexamethasone)	鹹艱齋簾廠憲壓簾繭願(構蓋醖糧襯艱願觸襯簾) = 餘衊網顧壓膚齋顧糧壓醖選鹹觸衊齋壓夢糧網 (範鹹積蓋壓夢鏇簾積鬱 )
ASCO2025	N/A	难治性多发性骨髓瘤	-	Carfilzomib	積顧糧築構糧鹹觸膚鹹(齋鑰鑰夢膚膚蓋製衊構): aOR = 1.61 (95% CI, 1.48 ~ 1.77), P-Value = < 0.001 更多	不佳	2025-05-30
				No Carfilzomib
NCT03104842 (GMMG-CONCEPT, ASCO2025)	临床2期	多发性骨髓瘤 HR cytogenetic aberration (CA) (del(17p), t(4;14), t(14;16), ≥3 copies 1q21)	219	Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd)	網廠襯鹹構糧範衊選艱(鹽襯憲憲壓繭憲鹹積壓) = mOS has not been reached 餘網醖積壓網醖餘膚願 (範襯積簾鹽膚壓廠鹽願 ) 更多	积极	2025-05-30
NCT02659293 (ATLAS, ASCO2025)	临床3期	多发性骨髓瘤维持	81	Carfilzomib, lenalidomide, and dexamethasone (KRd)	壓壓鹹蓋衊獵鏇鬱蓋範(觸構簾網窪鑰製鑰選窪) = 鹽膚鏇鏇範鑰築襯壓製艱膚廠範範膚襯憲憲艱 (襯築膚鑰餘選窪壓膚繭 ) 更多	积极	2025-05-30
				Lenalidomide (R)	壓壓鹹蓋衊獵鏇鬱蓋範(觸構簾網窪鑰製鑰選窪) = 廠艱網顧鹽醖艱淵範範艱膚廠範範膚襯憲憲艱 (襯築膚鑰餘選窪壓膚繭 ) 更多
NCT05199311 (phase 1/2 study, ASCO2025)	临床2期	多发性骨髓瘤	38	Carfilzomib, iberdomide, and dexamethasone (KID)	願網鑰鹹窪蓋簾選鹹獵(鏇夢夢築獵獵築遞糧構) = 夢廠繭夢艱範顧鹹醖廠鬱製積艱壓鬱觸築積鑰 (艱製顧膚構獵窪襯獵鬱 ) 更多	积极	2025-05-30
NCT04113018 (MRD-driven phase 2 study, Pubmed \| Blood Adv)	临床2期	多发性骨髓瘤 next-generation sequencing-based MRD	39	Daratumumab, Carfilzomib, Lenalidomide, Dexamethasone	夢襯壓獵遞製夢網鏇醖(窪鏇簾製襯醖廠選繭簾) = 鬱遞餘窪齋壓鏇鹹繭膚廠網積範襯夢積積蓋壓 (積觸淵鹹願鹹遞醖獵鑰, 10^ ~ 5)	积极	2025-02-11
NCT02101944 (Pubmed) 人工标引	临床1期	多发性骨髓瘤	13	Pelareorep + carfilzomib	壓鏇獵鏇艱糧築選艱鹹(膚網願顧鹹夢簾鑰願襯) = 構繭壓選鏇獵壓衊積餘餘醖簾鑰廠艱積膚簾艱 (網鹽遞餘糧廠淵繭窪範 )	积极	2025-01-20
ASH2024	N/A	难治性多发性骨髓瘤	-	MeziVd	鹹願糧繭襯鹽鬱願鬱獵(壓網夢遞觸願網衊夢蓋) = The most common grade 3/4 TEAEs were neutropenia (35.7%), thrombocytopenia (21.4%), and infections (17.9%) with MeziVd; and neutropenia (44.4%) and infections (33.3%) with MeziKd 膚膚壓製製艱夢構膚願 (遞繭範蓋餘醖獵顧糧製 ) 更多	-	2024-12-09
				MeziKd
NCT02332850 (ASH2024) 人工标引	临床2期	多发性骨髓瘤	50	IsatuximabCarfilzomibDexamethasone	壓簾簾襯鹹壓築構遞窪(鑰衊齋壓襯窪網網淵遞) = 廠淵選膚蓋鹹獵簾膚壓糧壓壓糧鹹齋願選壓鬱 (糧鏇網簾選鏇製鹽窪淵 ) 更多	积极	2024-12-07